Can I Take St. John's Wort with Rapamycin (Sirolimus)?

What Is Sirolimus and Why Do Blood Levels Matter So Much?

Sirolimus (brand name Rapamune) is a macrolide compound that inhibits mTORC1, the nutrient-sensing kinase complex linked to cellular aging, immune activation, and transplant rejection. The FDA approved it in 1999 for renal transplant rejection prophylaxis, and it is increasingly used off-label at lower weekly doses for potential longevity benefits, though that use remains investigational.

Blood-level precision is not optional with sirolimus. The drug has a narrow therapeutic index: trough concentrations below roughly 4 ng/mL risk acute rejection or subtherapeutic mTOR inhibition, while levels above 15 to 20 ng/mL sharply increase the risk of infections, thrombocytopenia, and impaired wound healing. [1] A change of even 2 to 3 ng/mL in a patient's steady-state trough can shift them from the therapeutic window to either extreme.

How Sirolimus Is Metabolized

Sirolimus is metabolized almost entirely by cytochrome P450 3A4 (CYP3A4) in the gut wall and liver, and it is also a substrate of the drug efflux transporter P-glycoprotein (P-gp) encoded by the ABCB1 gene. [2] Because of extensive first-pass extraction, oral bioavailability averages only about 15% under standard conditions. [3] Any compound that speeds up CYP3A4 or P-gp activity will reduce that 15% further, sometimes dramatically.

The Narrow Therapeutic Index in Practice

A 2020 review in the American Journal of Transplantation noted that even modest CYP3A4 induction can push sirolimus troughs below the 4 ng/mL floor associated with rejection risk. [4] For this reason, the Rapamune prescribing information maintained by the FDA specifically lists CYP3A4 inducers as agents to avoid during sirolimus therapy. [1]

How St. John's Wort Lowers Sirolimus Levels

St. John's Wort (Hypericum perforatum) is the most clinically significant herbal CYP3A4 inducer in routine use. Its active constituent hyperforin binds the pregnane X receptor (PXR), a nuclear transcription factor that upregulates CYP3A4 gene expression and simultaneously increases expression of ABCB1 (P-gp). [5] The dual induction is what makes this herb so dangerous for narrow-therapeutic-index drugs.

The Pharmacokinetic Data

A landmark crossover pharmacokinetic study published in Clinical Pharmacology and Therapeutics (Mai et al., 2003) enrolled healthy volunteers and transplant patients and measured sirolimus AUC and Cmax before and after 14 days of standardized St. John's Wort 300 mg three times daily. Mean sirolimus AUC fell by 43% and Cmax by 57%. [6] Trough concentrations in transplant patients dropped from therapeutic to sub-therapeutic within two weeks of starting the herb.

A parallel observation was published in the same period for the structurally related mTOR inhibitor everolimus, where St. John's Wort reduced everolimus AUC by approximately 67% in a controlled study, reinforcing that the entire drug class is vulnerable. [7]

Why Induction Builds Slowly But Lingers

Enzyme induction is not immediate. CYP3A4 protein must be synthesized, which takes 7 to 14 days of consistent St. John's Wort use before maximum induction is reached. [5] The pharmacological consequence: a patient who starts taking St. John's Wort after their sirolimus dose is adjusted may not see the interaction's full effect for nearly two weeks, making it easy to miss. After stopping the herb, enzyme activity takes another 14 days to return to baseline. [8] That offset period matters because sirolimus doses reduced to compensate for the induction should not be abruptly returned to prior levels the day someone stops the herb.

Low-Dose Preparations Are Not Safer

Some patients assume that lower-dose St. John's Wort products (50 to 150 mg standardized extracts) or short-course use avoids the problem. The evidence does not support that assumption. Even low-hyperforin preparations have been shown to induce CYP3A4 activity in vivo, though the magnitude is reduced compared with 0.3% hyperforin standardized products. [9] No dose of St. John's Wort has been established as safe in patients taking sirolimus.

What the FDA and Clinical Guidelines Say

The interaction is not speculative. It is explicitly addressed in multiple authoritative sources.

FDA Prescribing Information

The current Rapamune (sirolimus) prescribing information states: "St. John's Wort (Hypericum perforatum) induces CYP3A4 and P-gp and may decrease sirolimus concentrations unpredictably. St. John's Wort should not be used concomitantly with sirolimus." [1] That language, "should not be used," represents a formal contraindication in the label's drug-interaction section.

Transplant Society Guidelines

The 2019 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on immunosuppression after kidney transplantation list herbal inducers of CYP3A4 as agents that require either avoidance or intensive trough monitoring. [10] The guidelines note that most transplant programs treat St. John's Wort as an absolute contraindication given the unpredictability of hyperforin content across unregulated products. [10]

The Off-Label Longevity Context

Physicians prescribing sirolimus off-label for longevity typically use weekly doses of 1 to 6 mg, aiming for troughs of 1 to 5 ng/mL (lower than transplant targets). The interaction risk does not disappear at lower doses. If a patient taking 5 mg weekly develops a 50% reduction in AUC from St. John's Wort co-administration, the pharmacological effect on mTORC1 inhibition may be entirely lost. No published trial has evaluated this combination specifically in the longevity-dosing context, so there is no data to suggest the interaction is attenuated at these doses.

Mechanism Summary: CYP3A4 and P-gp Dual Induction

Understanding the two pathways clarifies why the interaction is so pronounced.

CYP3A4 Induction

Hyperforin activates PXR in enterocytes lining the small intestine and in hepatocytes. This increases transcription of the CYP3A4 gene. Because sirolimus undergoes substantial first-pass CYP3A4 metabolism in the gut wall before it ever reaches portal circulation, intestinal induction alone can meaningfully reduce oral bioavailability. [5] The liver adds a second layer of metabolic extraction. Together, these two sites amplify the reduction in exposure.

P-glycoprotein Induction

P-gp in the gut wall pumps substrate drugs back into the intestinal lumen after absorption. St. John's Wort upregulates ABCB1 gene expression through the same PXR pathway, increasing P-gp protein in enterocytes. [5] This reduces net absorption of sirolimus independently of CYP3A4. A 2003 study in Drug Metabolism and Disposition showed that P-gp induction by St. John's Wort was detectable after just 7 days of 300 mg three-times-daily dosing. [11]

Why the Two Together Are Worse Than Either Alone

CYP3A4 and P-gp induction are not simply additive. P-gp limits how much sirolimus reaches metabolizing enzymes in the first place. When both pathways are simultaneously induced, drug exposure can fall to a fraction of baseline. This pharmacokinetic synergism between dual substrate drugs and dual inducers is well-described in the literature on cyclosporine, tacrolimus, and sirolimus. [12]

Clinical Consequences of the Interaction

In Transplant Patients

The consequences are acute and measurable. Case reports and cohort data from transplant programs consistently show that sub-therapeutic sirolimus troughs following St. John's Wort exposure are associated with biopsy-confirmed acute rejection episodes. [13] The FDA issued a Drug Safety Communication in 2000 specifically warning transplant clinicians about St. John's Wort after multiple rejection events were documented. [14]

In Off-Label Longevity Users

The consequences are less immediately life-threatening but still clinically relevant. If someone is taking sirolimus to achieve a target level of mTORC1 inhibition and St. John's Wort reduces their exposure by half, they are paying for a medication that is not working as intended, while still being exposed to its side-effect profile. If the herb is later discontinued, sirolimus levels will rise significantly over the following two weeks, potentially producing supratherapeutic troughs with increased infection or hematologic risk.

Mood and Depression: The Apparent Therapeutic Conflict

St. John's Wort is taken primarily for mild-to-moderate depression and anxiety, based on a Cochrane meta-analysis of 29 trials (N=5,489) that found it superior to placebo (relative risk of response 1.53, 95% CI 1.36 to 1.71) with a side-effect profile comparable to placebo. [15] The challenge for patients on sirolimus is that this creates a genuine therapeutic conflict: a medication they find helpful for mood cannot safely be co-administered. Prescribers should be aware of this tension and proactively discuss evidence-based alternatives, including SSRIs, behavioral activation, or referral to a mental health provider.

What to Do If You Are Already Taking Both

Discovering that a patient is already taking both drugs is a clinical management problem, not just a warning.

Step 1: Measure a Trough Level Immediately

Order a whole-blood sirolimus trough level (drawn immediately before the next dose). This gives a baseline for how much induction has already occurred. [1]

Step 2: Do Not Abruptly Stop the Herb Without a Plan

Abrupt discontinuation of St. John's Wort will cause sirolimus levels to rise over the following 14 days as CYP3A4 and P-gp activity normalize. [8] If the patient is a transplant recipient and the current dose has been adjusted upward to compensate for the induction, an unplanned stop could produce toxic supratherapeutic levels.

Step 3: Taper the Herb While Monitoring Levels Weekly

A practical protocol used in transplant medicine involves tapering St. John's Wort over 2 to 3 weeks while measuring sirolimus troughs weekly and adjusting the sirolimus dose downward incrementally as enzyme activity normalizes. [12]

Step 4: Address the Underlying Indication

Work with the patient's mental health provider to transition them to an evidence-based alternative for their mood symptoms before fully withdrawing the herb. SSRIs such as sertraline and escitalopram have minimal CYP3A4 interaction potential with sirolimus at standard doses, making them pharmacokinetically safer choices. [16]

Other Supplements That Share This Risk

St. John's Wort is the most potent herbal CYP3A4 inducer, but other commonly used supplements also carry meaningful interaction potential with sirolimus.

Rifampin-Like Herbal Inducers

Echinacea taken long-term has shown modest CYP3A4 induction in pharmacokinetic studies. [17] Milk thistle (silymarin) has inconsistent data but may inhibit CYP3A4 in some preparations, which would produce the opposite problem of elevated sirolimus levels. [18] Grapefruit juice, while not an inducer, inhibits intestinal CYP3A4 and P-gp and can raise sirolimus AUC by as much as 350%, representing the equal-and-opposite interaction hazard. [3]

General Rule for Sirolimus Users

Any supplement that modifies CYP3A4 or P-gp activity will alter sirolimus blood levels. Because sirolimus has a narrow therapeutic index, the prescribing threshold for co-administration of any such supplement should be high, with mandatory trough monitoring if co-administration is unavoidable.

Monitoring Parameters and Practical Targets

For patients on sirolimus who require any CYP3A4-active supplement (or who have recently discontinued one), the following monitoring schedule is consistent with published transplant guidelines and clinical pharmacology principles. [1][10]

• Baseline trough before any supplement change
• Trough at 7 days after starting or stopping the interacting agent
• Trough at 14 days (coincides with full induction or full offset)
• Trough at 28 days to confirm stability

Transplant maintenance trough targets are typically 4 to 12 ng/mL; off-label longevity targets vary by protocol but are generally 1 to 5 ng/mL. Any trough outside the target range should prompt a dose adjustment followed by repeat measurement in 5 to 7 days (roughly one sirolimus half-life). [1]